ATE407692T1 - Medizinische zusammensetzungen zur behandlung und vorbeugung von auf abnormaler blutgerinnung basierenden erkrankungen - Google Patents

Medizinische zusammensetzungen zur behandlung und vorbeugung von auf abnormaler blutgerinnung basierenden erkrankungen

Info

Publication number
ATE407692T1
ATE407692T1 AT00987688T AT00987688T ATE407692T1 AT E407692 T1 ATE407692 T1 AT E407692T1 AT 00987688 T AT00987688 T AT 00987688T AT 00987688 T AT00987688 T AT 00987688T AT E407692 T1 ATE407692 T1 AT E407692T1
Authority
AT
Austria
Prior art keywords
blood coagulation
prevention
treatment
pharmaceutical composition
blood clotting
Prior art date
Application number
AT00987688T
Other languages
English (en)
Inventor
Yasushi Nakatomi
Kazuhiko Tomokiyo
Tatsuya Araki
Kaori Teshima
Tomoko Watanabe
Tomohiro Nakagaki
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE407692T1 publication Critical patent/ATE407692T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT00987688T 1999-12-24 2000-12-21 Medizinische zusammensetzungen zur behandlung und vorbeugung von auf abnormaler blutgerinnung basierenden erkrankungen ATE407692T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP36812299A JP4676585B2 (ja) 1999-12-24 1999-12-24 血液凝固異常に基づく疾患の治療・予防用医薬組成物

Publications (1)

Publication Number Publication Date
ATE407692T1 true ATE407692T1 (de) 2008-09-15

Family

ID=18491024

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00987688T ATE407692T1 (de) 1999-12-24 2000-12-21 Medizinische zusammensetzungen zur behandlung und vorbeugung von auf abnormaler blutgerinnung basierenden erkrankungen

Country Status (9)

Country Link
US (1) US6881721B2 (de)
EP (1) EP1240901B1 (de)
JP (1) JP4676585B2 (de)
CN (1) CN1222311C (de)
AT (1) ATE407692T1 (de)
DE (1) DE60040236D1 (de)
DK (1) DK1240901T3 (de)
ES (1) ES2312374T3 (de)
WO (1) WO2001047548A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1254273C (zh) * 2001-07-10 2006-05-03 财团法人化学及血清疗法研究所 药学上稳定的止血组合物
JP2007055899A (ja) * 2003-10-27 2007-03-08 Chemo Sero Therapeut Res Inst 血液凝固第ｘ因子を主剤とする血液凝固異常に基づく疾患の治療・予防用医薬組成物
WO2005107795A1 (en) * 2004-05-11 2005-11-17 Novo Nordisk Health Care Ag Use of factor viia for the treatment of burn traumas
WO2008023052A1 (en) * 2006-08-24 2008-02-28 Novo Nordisk Health Care Ag Combination of a fvii and a thrombin-activable factor x
WO2009028573A1 (ja) 2007-08-27 2009-03-05 National University Corporation Nagoya University 血液凝固障害におけるリバビリンの利用
AU2011237383B2 (en) 2010-04-08 2014-03-27 Hemosonics, Llc Hemostatic parameter display

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287180A (en) 1980-01-28 1981-09-01 Baxter Travenol Laboratories, Inc. Method for treating blood clotting factor inhibitors
US4357321A (en) * 1980-01-28 1982-11-02 Baxter Travenol Laboratories, Inc. Method and composition for treating clotting factor inhibitors
WO1981002105A1 (en) 1980-01-28 1981-08-06 Baxter Travenol Lab Therapeutic compositions & methods for manufacture and use
US4663164A (en) 1980-01-28 1987-05-05 Baxter Travenol Laboratories, Inc. Aqueous compositions for treating blood clotting factor inhibitors
US4286056A (en) 1980-01-28 1981-08-25 Baxter Travenol Laboratories, Inc. Method for making therapeutic enzyme compositions
US4459288A (en) * 1981-05-11 1984-07-10 Baxter Travenol Laboratories, Inc. Therapeutic blood clotting factor compositions and their use
US4382083A (en) * 1981-06-25 1983-05-03 Baxter Travenol Laboratories, Inc. Therapeutic method for treating blood-clotting defects with factor VIIa
US4501731A (en) * 1983-06-27 1985-02-26 Tishkoff Garson H Treatment of disparate bleeding disorders with factor X zymogen
JP2824430B2 (ja) 1989-08-02 1998-11-11 財団法人化学及血清療法研究所 血液凝固第▲ｖｉｉ▼因子または活性型血液凝固第▲ｖｉｉ▼因子の調製方法
DE4325872C1 (de) * 1993-08-02 1994-08-04 Immuno Ag Virusinaktivierte Faktor Xa-Präparation
JP3810080B2 (ja) * 1994-04-22 2006-08-16 ステイヒテイング・セントラール・ラボラトリウム・バン・デ・ブレドトランスフシーデイーンスト・バン・ヘト・ネーデルランドセ・ロデ・クルイス 血液凝固カスケードにおける疾患を検出および治療するための方法および手段
DE19531637A1 (de) * 1995-08-28 1997-03-06 Immuno Ag Pharmazeutische Zusammensetzung zur Behandlung von Blutgerinnungsstörugnen, Verfahren zur Herstellung derselben und deren Verwendung
JPH1059866A (ja) 1996-08-19 1998-03-03 Chemo Sero Therapeut Res Inst 血液凝固第ｖｉｉ因子及び／もしくは活性化血液凝固第ｖｉｉ因子の製造方法
JP4046377B2 (ja) 1996-08-19 2008-02-13 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子の活性化方法及び該方法に基づく活性化血液凝固第ｖｉｉ因子の製造方法

Also Published As

Publication number Publication date
WO2001047548A1 (fr) 2001-07-05
JP2001181204A (ja) 2001-07-03
DK1240901T3 (da) 2008-11-10
EP1240901A4 (de) 2005-01-12
EP1240901B1 (de) 2008-09-10
US20030060411A1 (en) 2003-03-27
CN1434720A (zh) 2003-08-06
JP4676585B2 (ja) 2011-04-27
EP1240901A1 (de) 2002-09-18
CN1222311C (zh) 2005-10-12
US6881721B2 (en) 2005-04-19
ES2312374T3 (es) 2009-03-01
DE60040236D1 (de) 2008-10-23

Similar Documents

Publication Publication Date Title
Carless et al. Fibrin sealant use for minimising peri‐operative allogeneic blood transfusion
EP0726749B1 (de) Hämostatisches pflaster
Allam et al. In vivo effects of zoledronic acid on oral mucosal epithelial cells
CA2931174A1 (en) No-emitting medical dressing comprising an no-generating module and a radiation-emitting module
Hampton et al. Tissue viability
ATE292979T1 (de) Verwendung von aktiviertem protein-c zur behandlung überschiessender blutgerinnung bei sepsis
Longhurst Emergency treatment of acute attacks in hereditary angioedema due to C1 inhibitor deficiency: what is the evidence?
Liu et al. Tranexamic acid reduces occult blood loss, blood transfusion, and improves recovery of knee function after total knee arthroplasty: a comparative study
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
Lee et al. Haemophilia and advanced fibrin sealant technologies
Zhao et al. Comprehensive assessment of tranexamic acid during orthognathic surgery: a systematic review and meta-analysis of randomized, controlled trials
Tuthill et al. Assessment of topical hemostats in a renal hemorrhage model in heparinized rats
BR9910899A (pt) Compostos de ácido sulfÈnico ou sulfonilamino n-(hetero-aralquil)-azaeterocicliamida
ATE407692T1 (de) Medizinische zusammensetzungen zur behandlung und vorbeugung von auf abnormaler blutgerinnung basierenden erkrankungen
P Kuffler Techniques for wound healing with a focus on pressure ulcers elimination
Hasegawa et al. Wound, pressure ulcer and burn guidelines–1: Guidelines for wounds in general
Petratos et al. Transforming growth factor‐β2 (TGF‐β2) reverses the inhibitory effects of fibrin sealant on cutaneous wound repair in the pig
EP1240900A4 (de) Medizinische zusammensetzungen zur prävention und behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen
Shetty Effectiveness of intravenous haemocoagulase on haemorrhage control in bi-maxillary orthognathic surgery—a prospective, randomised, controlled, double-blind study
Wilde Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors
Matocha Postsurgical complications
Aslam Double blind study on the efficacy of local application of haemocoagulase solution in wound healing
Shander et al. Acquired hemophilia presenting as profound hematuria: evaluation, diagnosis, and management of elusive cause of bleeding in the emergency department setting
DE59909356D1 (de) Pharmazeutische präparation, enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen
Lu et al. Hemocoagulase agkistrodon can prevent bleeding and induce hypofibrinogenemia in hepatic disease cases

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1240901

Country of ref document: EP